CARsgen Therapeutics Holdings Limited
科濟藥業控股有限公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2171)

VOLUNTARY ANNOUNCEMENT
ABSTRACTS FROM THE ONGOING STUDIES OF ZEVORCABTAGENE AUTOLEUCEL AND CT071 ARE TO BE PRESENTED AS AN ORAL PRESENTATION AND A POSTER PRESENTATION, RESPECTIVELY, AT THE UPCOMING EHA 2024

This announcement is made by CARsgen Therapeutics Holdings Limited (the "**Company**", together with its subsidiaries and consolidated affiliated entities, the "**Group**" or "**CARsgen**") on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business update of the Group.

The board of directors of the Company (the "**Board**") announces that the abstracts of zevorcabtagene autoleucel (R&D code: CT053, an autologous CAR-T product against BCMA) and CT071, an autologous CAR T-cell therapy candidate targeting G protein-coupled receptor class C group 5 member D (GPRC5D), have been accepted for oral presentation and poster presentation, respectively, at the 29th Annual Congress of the European Hematology Association ("**EHA**"). Details are set out below:

Abstract Title	Abstract Number	Publication Type	Abstract Release Time (CEST)
PHASE 2 STUDY OF FULLY HUMAN BCMA-TARGETING CAR-T CELLS (ZEVORCABTAGENE AUTOLEUCEL) IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA	S209	Oral presentation	May 14, 2024, at 16:00
FIRST-IN-HUMAN STUDY OF GPRC5D-TARGETED CAR T CELLS (CT071) WITH AN ACCELERATED MANUFACTURING PROCESS IN PATIENTS WITH RELAPSED/ REFRACTORY MULTIPLE MYELOMA (RRMM)	P941	Poster presentation	May 14, 2024 at 16:00

ABOUT ZEVORCABTAGENE AUTOLEUCEL

Zevorcabtagene autoleucel is a fully human, autologous BCMA CAR T-cell product for the treatment of relapsed/refractory multiple myeloma ("**R/R MM**"). As informed by the NMPA on March 1, 2024, zevorcabtagene autoleucel was approved on February 23, 2024 for the treatment of adult patients with R/R MM who have progressed after at least 3 prior lines of therapy (including a proteasome inhibitor and immunomodulatory agent). CARsgen is conducting a separate Phase 1b/2 LUMMICAR STUDY 2 clinical trial in North America to evaluate the safety and efficacy of zevorcabtagene autoleucel in R/R MM.

Zevorcabtagene autoleucel received Regenerative Medicine Advanced Therapy (RMAT) and Orphan Drug designations from the U.S. FDA in 2019, as well as Priority Medicines (PRIME) and Orphan Medicinal Product designations from the European Medicines Agency (EMA) in 2019 and 2020, respectively. Zevorcabtagene autoleucel also received Breakthrough Therapy designation from the NMPA in 2020.

ABOUT CT071

CT071 is a CAR T-cell therapy candidate developed utilizing proprietary CARcelerate™ platform of CARsgen targeting GPRC5D for the treatment of R/R MM or relapsed/refractory plasma cell leukemia ("**R/R PCL**"). An IIT (NCT05838131) is ongoing in China to evaluate the safety and efficacy of CT071 for the treatment of R/R MM or R/R PCL.

ABOUT THE COMPANY

CARsgen is a biopharmaceutical company with operations in China and the U.S. and is focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors. CARsgen has established a comprehensive CAR T-cell research and development platform, encompassing target discovery, innovative CAR T-cell development, clinical trials, and commercial-scale production. CARsgen has internally developed novel technologies and a product pipeline with global rights to address major challenges of CAR T-cell therapies, such as improving the safety profile, enhancing the efficacy in treating solid tumors, and reducing treatment costs. CARsgen's mission is to become a global biopharmaceutical leader that brings innovative and differentiated cell therapies to cancer patients worldwide and makes cancer curable.

DEFINITIONS AND GLOSSARY OF TECHNICAL TERMS

"BCMA"	B-cell maturation antigen, a protein that is highly expressed in a number of hematologic malignancies
"CAR"	chimeric antigen receptor
"CAR T"	chimeric antigen receptor T cell
"EMA"	European Medicines Agency
"FDA" or "U.S. FDA"	U.S. Food and Drug Administration
"GPRC5D"	G protein-coupled receptor, class C, group 5, member D, GPRC5D, a protein that is highly expressed on the surface of malignant plasma cells with limited expression on normal tissues
"Phase Ib"	a phase of clinical trials that primarily assesses safety, tolerability and pharmacokinetics/pharmacodynamics at multiple ascending dose levels prior to commencement of a Phase II or Phase III clinical trial
"Phase II clinical trial"	a study in which a drug is administered to a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the drug for a specific targeted disease, and to determine dosage tolerance and optimal dosage
"PRIME"	PRIority MEdicine. A scheme launched by the EMA to offer early and proactive support to medicine developers to optimize the generation of robust data on a medicine's benefits and risks, and to accelerate the assessment of the applications of medicines that target an unmet medical need with advantages over existing treatments
"regenerative medicine advanced therapy" or "RMAT"	a special status granted by the FDA to regenerative medicine therapies, including cell therapies, that are intended to treat a serious or life-threatening disease or condition, and for which preliminary clinical evidence indicates that the drug has the potential to address unmet medical needs for such a disease or condition
"United States" or "U.S."	the United States of America, its territories, its dependencies and all areas subject to its jurisdiction

Cautionary Statement required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: The Company cannot guarantee that it will be able to develop, or ultimately market, zevorcabtagene autoleucel and CT071, successfully. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

Cautionary-Language Regarding Forward-Looking Statements

All statements in this announcement that are not historical fact or that do not relate to present facts or current conditions are forward-looking statements. Such forward-looking statements express the Group's current views, projections, beliefs and expectations with respect to future events as of the date of this announcement. Such forward-looking statements are based on a number of assumptions and factors beyond the Group's control. As a result, they are subject to significant risks and uncertainties, and actual events or results may differ materially from these forward-looking statements and the forward-looking events discussed in this announcement might not occur. Such risks and uncertainties include, but are not limited to, those detailed under the heading "Principal Risks and Uncertainties" in our most recent annual report and interim report and other announcements and reports made available on our corporate website, https://www.carsgen.com. No representation or warranty is given as to the achievement or reasonableness of, and no reliance should be placed on, any projections, targets, estimates or forecasts contained in this announcement.

By order of the Board
CARsgen Therapeutics Holdings Limited
Dr. Zonghai LI
Chairman

Hong Kong, April 30, 2024

As at the date of this announcement, the board of directors of the Company comprises Dr. Zonghai LI, Dr. Huamao WANG and Dr. Hua JIANG as executive Directors; Mr. Bingsen GUO, Mr. Huaqing GUO and Mr. Ronggang XIE as non-executive Directors; Dr. Guangmei YAN, Ms. Xiangke ZHAO and Dr. Wen ZHOU as the independent non-executive Directors.

In the case of inconsistency, the English text of this announcement shall prevail over the Chinese text.